PDF
ePub
Citation
Print
Abstract
Background
Essential thrombocythemia (ET) is thought to reflect transformation of a multipotent hematopoietic stem cell, but its molecular pathogenesis remains obscure. But tyrosine kinase, especially Janus kinase 2 (JAK2), has been implicated in myeloproliferative disorders other than chronic myeloid leukemia. We investigated the frequency of JAK2 mutation and its correlation with other clinicopathologic variables in Korean patients with ET and reactive thrombocytosis (RT).
Methods
JAK2 mutation analysis was performed on genomic DNA from bone marrow aspirates of 24 patients with ET and peripheral blood in 36 patients with RT using allele-specific PCR.
Results
JAK2 mutation was detected in 11 patients (46%) among the 24 patients with ET and was not found in 36 patients with RT. In patients with ET, older age and leukocytosis were related with JAK2 mutation without statistical significance (P=0.172 and 0.094, respectively). But this mutation was not correlated with sex, hemoglobin, platelet count, splenomegaly, increased cellularity of bone marrow, bone marrow fibrosis and vascular complications.
References
1. Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol. 2005; 42:230–8.
2. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005; 131:208–13.
3. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005; 80:947–58.
4. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005; 106:2920–1.
5. Johan MF, Goodeve AC, Bowen DT, Frew ME, Reilly JT. JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia. Br J Haematol. 2005; 130:968.
6. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005; 106:1207–9.
7. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005; 280:22788–92.
8. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7:387–97.
9. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 2005; 434:1144–8.
10. Baxter FJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365:1054–61.
11. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006; 107:4214–22.
12. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocytes growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000; 96:3310–21.
13. Westwood NB, Pearson TC. Diagnostic application of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma. 1996; 22(S1):):S95–103.
14. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981; 58:916–9.
15. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, et al. Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005; 131:166–71.
16. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106:2162–8.
17. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML and megakaryocytic leukemia. Blood. 2005; 106:3370–3.
18. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005; 106:3377–9.
19. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med. 2005; 352:1744–6.
20. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352:1779–90.
Fig. 1.
Allele-specific PCR in patients with ET and RT. The 364 bp of PCR product is an internal control and 203bp is an allele specific product. Lane SM, molecular size marker; lane 1, 2, and 7, positive results from ET patients; lane 4, 5, 6, negative results from RT patients; lane 3, negative control.
Abbreviations: ET, essential thrombocytopenia; RT, reactive thrombocytosis.
Table 1.
Characteristics of 24 patients with essential thrombocythemia
Table 2.
Caracteristics of 36 patients with reactive thrombocytosis
Table 3.
Clinical variables according to the mutational status of JAK2
XML Download